US lawmakers present no evidence of Russia’s interference in US election - Russian MPRussian Politics & Diplomacy February 23, 21:42
Russia to continue strengthen its Armed Forces - PutinRussian Politics & Diplomacy February 23, 21:37
4,000 Russian nationals fight among militants in Syria - PutinRussian Politics & Diplomacy February 23, 21:31
Opposition’s demand of Assad’s immediate resignation absurd - Russian envoy to GenevaRussian Politics & Diplomacy February 23, 16:34
Moscow celebrates Defender of the Fatherland DaySociety & Culture February 23, 16:19
ISS astronauts capture Dragon with manipulatorScience & Space February 23, 14:36
Vitaly Churkin’s body delivered to RussiaRussian Politics & Diplomacy February 23, 12:30
Ukrainian military shell Donetsk water purification plantWorld February 23, 11:45
Scientists discover three Earth-sized exoplanets that may potentially harbor lifeScience & Space February 23, 5:50
ANNAPOLIS, Maryland, Sept. 15, 2015 /PRNewswire/ - The Plasma Protein Therapeutics Association (PPTA) and its member companies are sponsoring the third annual International Plasma Awareness Week, October 11-17.
Logo - http://photos.prnewswire.com/prnh/20150914/266390LOGO
Photo - http://photos.prnewswire.com/prnh/20140910/145293-INFO
International Plasma Awareness Week (IPAW) is designed to:
PPTA member companies have planned a variety of activities at plasma collection facilities in the U.S. and Europe. In addition, patient organizations representing individuals who rely on plasma protein therapies that treat rare diseases have pledged their support.
"Patients throughout the world rely on plasma protein therapies which are developed through the generosity and commitment of plasma donors. PPTA is proud of the contributions industry makes to saving and improving lives," said Joshua Penrod, PPTA Vice President, Source and International Affairs.
Plasma protein therapies, which include plasma-derived therapies and recombinant analogs, are used to treat chronic, life-threatening diseases including bleeding disorders, primary immune deficiencies, alpha-1 antitrypsin deficiency and certain rare neurological disorders. In addition, these therapies are used in emergency and surgical medicine.
There are more than 500 plasma collection facilities in Canada, Austria, Hungary, the Czech Republic, Germany, and the U.S. In addition to meeting regulatory requirements, the majority of these centers have achieved International Quality Plasma Program certification, PPTA's voluntary standards program that provides global leadership for the industry's goal of continuous improvement with a focus on safety and quality from the donor to the patient.
The Plasma Protein Therapeutics Association (PPTA), a global industry trade association, represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. Millions of people use these therapies worldwide to treat a variety of diseases and serious medical conditions. PPTA also administers standards and programs that help ensure the quality and safety of plasma protein therapies, donors and patients.
Rachel Liebe, Project Coordinator, Communications, +1.443.433.1118